A randomized, placebo-controlled, multiple dose, double blind, phase IIb, dose guiding trial to explore safety and tolerability of four weeks treatment with sulthiame in patients with moderate to severe obstructive sleep apnea
Latest Information Update: 24 Feb 2025
At a glance
- Drugs Sultiame (Primary)
- Indications Sleep apnoea syndrome
- Focus Adverse reactions
- Sponsors Desitin Pharmaceuticals GmbH
Most Recent Events
- 07 May 2022 Results presented at The joint congress on obesity of the European Association of the Study of Obesity and the International Federation for the Surgery of Obesity and metabolic disorders-European Chapter.
- 04 Mar 2022 New trial record